Dashboard
Manage Tickers

ITRMIterum Therapeutics plc

Nasdaq iterumtx.com


$ 1.07 $ -0.03 (-2.75 %)    

Monday, 16-Sep-2024 15:52:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 1.06
$ 1.04
$ 1.06 x 100
-- x --
$ 1.04 - $ 1.08
$ 0.62 - $ 2.50
195,530
na
24.07M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-25-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
09/10/2024 11:25:03

iterum-therapeutics-reports-fda-advisory-committee-discussion-of-oral-sulopenem-fda-decision-expected-by-pdufa-goal-date-of-october-25-2024
Iterum Therapeutics Reports FDA Advisory C...
09/10/2024 11:06:00

Iterum announced that a meeting of the FDA Antimicrobial Drugs Advisory Committee (AMDAC) took place on September 9, 2024 at wh...

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
09/10/2024 10:56:58

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $5 price target.

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
09/09/2024 10:55:03

hc-wainwright--co-maintains-buy-on-iterum-therapeutics-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on Iteru...
08/15/2024 11:10:47

HC Wainwright & Co. analyst Ed Arce maintains Iterum Therapeutics (NASDAQ:ITRM) with a Buy and lowers the price target f...

iterum-therapeutics-q2-2024-adj-eps-023-beats-045-estimate-cash-cash-equivalents-and-short-term-investments-were-117m-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics Q2 2024 Adj. EPS $(0.2...
08/14/2024 11:07:05

iterum-therapeutics-announces-expiration-and-results-of-rights-offering-estimates-that-it-will-receive-aggregate-gross-proceeds-of-74m-not-including-estimated-expenses-relating-to-the-rights-offering-and-payable-by-the-company-of-11m
Iterum Therapeutics Announces Expiration A...
08/06/2024 21:35:28

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

iterum-therapeutics-announces-uspto-notice-of-allowance-for-two-us-patents-and-issuance-of-canadian-patent-by-cipo-for-sulopenem-etzadroxil-and-probenecid-oral-sulopenem
Iterum Therapeutics Announces USPTO Notice...
08/02/2024 12:04:11

iterum-therapeutics-commences-121-per-unit-rights-offering-for-antibiotics-development
Iterum Therapeutics Commences $1.21 Per Un...
07/22/2024 11:43:09

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
06/21/2024 17:40:20

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announces-fda-to-review-new-drug-application-for-oral-sulopenem-etzadroxilprobenecid-for-uncomplicated-utis-in-advisory-committee-meeting-on-september-9-2024-discussion-to-focus-on-antimicrobial-stewardship-and-target-patient-population
Iterum Therapeutics Announces FDA To Revie...
06/21/2024 12:02:20

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/31/2024 16:40:39

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announced-that-the-us-fda-has-acknowledged-receipt-of-the-resubmission-of-the-nda-for-sulopenem-etzadroxilprobenecid-for-the-treatment-of-utis
Iterum Therapeutics Announced That The U.S...
05/31/2024 12:03:15

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/14/2024 10:41:55

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-cash-cash-equivalents-and-short-term-investments-were-182-million-at-march-31-2024-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics' Cash, Cash Equivalent...
05/13/2024 11:03:43

iterum-therapeutics-q1-2024-adj-eps-058-beats-072-estimate
Iterum Therapeutics Q1 2024 Adj EPS $(0.58...
05/13/2024 11:02:41

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/30/2024 10:37:41

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-resubmits-new-drug-application-to-fda-for-oral-sulopenem
Iterum Therapeutics Resubmits New Drug App...
04/29/2024 12:03:18

on-april-3-iterum-therapeutics-received-letter-from-nasdaq-indicating-that-it-is-not-in-compliance-with-nasdaq-listing-rule
On April 3, Iterum Therapeutics Received L...
04/05/2024 20:36:30

- SEC Filing

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/01/2024 10:23:51

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION